Center for Neuroendocrine Tumors
The UCSF Center for Neuroendocrine Tumors provides comprehensive care for patients with all types of neuroendocrine tumors (NETs). Arising from cells that have traits of both nerve cells and endocrine cells, these rare tumors may produce hormones and can develop in many parts of the body, including the head and neck, lungs, pancreas and digestive tract.
We're equipped to handle any NET, no matter where it appears in the body or how it behaves. Our team includes surgeons, medical oncologists, radiation oncologists, radiologists, cardiologists, endocrinologists, symptom management experts, genetic counselors, nutritionists, psychologists, social workers and other specialists. We work together to provide patients with a precise diagnosis and treatment plan tailored to their particular case and needs.
All of our patients can expect to receive the latest and most effective therapies available for their condition. For a patient with a pancreatic NET, for example, the best treatment might involve minimally invasive surgery to remove the tumor. A patient with a gastrointestinal tumor might benefit from peptide receptor radionuclide therapy (PRRT), a new radiation technique that targets cancer cells. And we might use advanced screening tools, such as the UCSF500 Cancer Gene Panel test, to identify the precise biology behind another patient's tumor.
Our goal is to deliver world-class care from a holistic perspective. We make sure that our patients and their families have the support they need to face the physical, emotional and financial challenges that can arise after a cancer diagnosis. UCSF offers a wide range of cancer support services, including a bimonthly education and support group for patients with NETs and their loved ones.
Our locations
Our team
-
Rahul Aggarwal
MD
Genitourinary oncologist -
Mekhail Anwar
MD, PhD
Radiation oncologist -
Carlos Corvera
MD, FACS
Gastrointestinal cancer surgeon -
Nicholas Fidelman
MD
Interventional radiologist -
Wesley Kidder
MD, MPH
Gastrointestinal oncologist -
Umesh Masharani
MBBS
Endocrinologist -
Lisa Mackie
NP, MSN
Nurse practitioner -
Eric Nakakura
MD, PhD
Gastrointestinal cancer surgeon -
Sorbarikor Piawah
MD, MPH
Gastrointestinal oncologist
Clinical trials
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...
Recruiting
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...
A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...
Recruiting
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...
The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...
Recruiting
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Recruiting
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine T...
The All Subjects as Treated (ASaT, ITT) population will be used for the analysis of ORR. The primary efficacy endpoint will be best observed Overall Response Rate (ORR) by RECIST 1.1 (investigator reported). ORR is defined as the ...
Recruiting
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Will be assessed per Response Evaluation Criteria in Solid Tumors 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The...
Recruiting
U.S. News rankings
-
Among the top hospitals in the nation
-
Best in Northern California for cancer care (tie)
Accreditations & memberships
-
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
-
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
-
National Comprehensive Cancer Network
UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Support services
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
